Literature DB >> 17888083

Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy.

José M Ruiz-Moreno, Javier A Montero, Francisco Lugo, Pedro Amat, Corina Staicu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17888083     DOI： 10.1111/j.1600-0420.2007.01021.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  6 in total

1.  Bevacizumab in vitreous haemorrhage secondary to radiation retinopathy.

Authors:  Javier Antonio Montero; Giovanni Yanez-Castro; Maria Eugenia Sanchis-Merino; Jose Maria Ruiz-Moreno
Journal:  BMJ Case Rep       Date:  2014-02-07

2.  Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study.

Authors:  Irini Chatziralli; Eleni Dimitriou; George Theodossiadis; Evgenia Bourouki; Eleni Bagli; George Kitsos; Panagiotis Theodossiadis
Journal:  Int Ophthalmol       Date:  2019-12-02       Impact factor: 2.031

3.  Change of Vascular Endothelial Growth Factor Levels following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy.

Authors:  Hui-Jin Chen; Zhi-Zhong Ma; Ying Li; Chang-Guan Wang
Journal:  J Ophthalmol       Date:  2019-10-23       Impact factor: 1.909

4.  Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Authors:  Frank S Ong; Jane Z Kuo; Wei-Chi Wu; Ching-Yu Cheng; Wendell-Lamar B Blackwell; Brian L Taylor; Wayne W Grody; Jerome I Rotter; Chi-Chun Lai; Tien Y Wong
Journal:  J Pers Med       Date:  2013

5.  Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy.

Authors:  Xi Shen; Yanwei Chen; Yanuo Wang; Lu Yang; Yisheng Zhong
Journal:  J Ophthalmol       Date:  2016-05-16       Impact factor: 1.909

6.  Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment.

Authors:  Reyin Lien; Mu-Hsien Yu; Kuang-Hung Hsu; Pei-Ju Liao; Yen-Po Chen; Chi-Chun Lai; Wei-Chi Wu
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.